AMRI has signed a five-year extension and expansion of its ongoing research collaboration with CHDI Foundation, Inc. (CHDI), focused on the discovery of new therapeutic agents for the treatment of Huntington’s disease (HD). Further deploying its fully integrated drug discovery services model, AMRI will apply a complete menu of integrated biology and chemistry capabilities including assay development, screening, library production, hit identification, ADMET, computer-aided drug discovery (CADD...